Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Enphase Energy Inc (ENPH) vs Cassava Sciences Inc (FLNA) Price & Performance

Enphase Energy IncTrade
Cassava Sciences IncTrade

Price performance (Past 24H)

Key statistics

Enphase Energy Inc vs Cassava Sciences Inc — how do they compare? Enphase Energy Inc trades at $42.35 (market cap $5.41B), while Cassava Sciences Inc trades at $0.97 (market cap $47.75M). The key difference: Enphase Energy Inc is far larger — about 113.3× Cassava Sciences Inc's market cap, and Enphase Energy Inc is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals.

ENPHFLNA
Market Cap
$5.41B$47.75M
Sector
TechnologyHealth
52-Week High
$72.33$4.64
52-Week Low
$26.12$0.87
Enterprise Value
$5.05B-$34.93M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Enphase Energy Inc

Enphase Energy (ENPH) trades at $41.87, up 5.55% with bullish technical signals and mixed quarterly earnings. The company reported Q2 2026 EPS of $0.46, missing expectations, while revenue declined 19.6% year-over-year. Recent product expansions in battery systems and U.S. manufacturing commitments provide growth catalysts, though residential solar demand remains volatile. Valuation metrics show a P/E of 41.46 and P/S of 4.2, reflecting premium pricing amid earnings normalization.

Outlook remains cautiously optimistic with analyst consensus price target of $45.37 offering 8% upside potential. Key opportunities include European storage growth and AI data center initiatives, while risks center on U.S. demand weakness and competitive pressures. The stock faces near-term resistance at $43-$45 levels with institutional ownership showing mixed positioning through recent filings.

Cassava Sciences Inc

FLNA trades at $0.995, up 3.75% today, with a bearish technical signal from moving averages but neutral oscillators. The company reported three consecutive quarterly earnings beats, with Q2 2026 EPS of -$0.18 beating expectations of -$0.225. Financials show negative cash flows and profitability, with ROE at -55.79% and net income of -$90.97M in 2025. Analyst consensus is strongly positive with 8 buy ratings out of 12.

Despite operational losses, FLNA's consistent earnings beats and strong analyst support suggest potential upside if clinical developments progress. Key risks include sustained cash burn, lack of revenue, and dependence on successful drug trials for Tuberous Sclerosis Complex. The stock remains speculative with high volatility expected.

Returns comparison

Trailing returns across standard periods

About Enphase Energy Inc

Enphase Energy is a global energy technology company. The company delivers smart, easy-to-use solutions that manage solar generation, storage, and communication on one platform. The company's microinverter technology primarily serves the rooftop solar market and produces a fully integrated solar-plus-storage solution. Geographically, it derives a majority of revenue from the United States.

Read more on ENPH

About Cassava Sciences Inc

Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease

Read more on FLNA